Concepedia

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients

Pia Leandersson, Anna Åkesson, Ingrid Hedenfalk, Susanne Malander, Christer Borgfeldt

PLoS ONE · 2020 · 34 citations · 35 references

DOIFull text

Open access

Abstract

HE4 was the best performing individual biomarker for discrimination between benign ovarian tumors and EOC including borderline tumors. The addition of other carcinogenesis-related biomarkers in a multiplex biomarker panel can improve the diagnostic performance of the established biomarkers HE4 and CA125.

References

35

Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability

Erika Assarsson, Martin Lundberg, Göran Holmquist et al. · PLoS ONE · 2014 · 1.8K citations · Full text

, , +27

Effect of Screening on Ovarian Cancer Mortality

Saundra S. Buys · JAMA · 2011 · 1.3K citations

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Ian Jacobs, Usha Menon, Andy Ryan et al. · The Lancet · 2015 · 1.1K citations · Full text

A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

Ian Jacobs, D Oram, J. Fairbanks et al. · BJOG An International Journal of Obstetrics & Gynaecology · 1990 · 953 citations

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

Richard G. Moore, D. Scott McMeekin, Amy Brown et al. · Gynecologic Oncology · 2008 · 852 citations

, , +8